Spark Therapeutics (ONCE) Given a $105.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

“This morning, Spark announced initial plans on U.S. pricing, including a wholesale acquisition cost for LUXTURNA of $425,000/eye ($850,000/ patient).”,” Cantor Fitzgerald’s analyst commented.

ONCE has been the topic of a number of other research reports. Cowen reissued a buy rating and set a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial restated a buy rating and set a $75.00 price target on shares of Spark Therapeutics in a research report on Thursday, December 7th. Barclays boosted their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an overweight rating in a research report on Friday, October 13th. Chardan Capital restated a buy rating and set a $100.00 price target on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, BMO Capital Markets set a $73.00 price target on shares of Spark Therapeutics and gave the company a buy rating in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $76.03.

Shares of Spark Therapeutics (ONCE) traded down $3.92 during mid-day trading on Wednesday, reaching $51.84. 1,785,400 shares of the company’s stock were exchanged, compared to its average volume of 1,199,500. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75. The company has a market cap of $1,870.00 and a PE ratio of -7.20.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. During the same period in the previous year, the firm earned ($1.07) EPS. The company’s revenue was up 45.8% compared to the same quarter last year. research analysts expect that Spark Therapeutics will post -7.58 earnings per share for the current fiscal year.

In related news, insider Daniel Faga sold 6,000 shares of the company’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $79.95, for a total value of $479,700.00. Following the completion of the transaction, the insider now directly owns 6,000 shares in the company, valued at $479,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $876,750. The disclosure for this sale can be found here. Insiders sold 62,309 shares of company stock valued at $4,621,085 over the last quarter. 7.30% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in ONCE. Ameritas Investment Partners Inc. grew its position in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics in the second quarter worth $143,000. BNP Paribas Arbitrage SA grew its position in Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 2,449 shares in the last quarter. Pacad Investment Ltd. grew its position in Spark Therapeutics by 75.0% in the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Spark Therapeutics in the third quarter worth $225,000. Institutional investors own 94.91% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Spark Therapeutics (ONCE) Given a $105.00 Price Target by Cantor Fitzgerald Analysts” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://transcriptdaily.com/2018/01/05/spark-therapeutics-once-given-a-105-00-price-target-by-cantor-fitzgerald-analysts.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply